• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.25
  • VXN 17.82
  • VXO 15.25
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies. Its technology platforms comprise PEGylation Technology designed to enhance the performance of various drug classes, including macromolecules, small molecules, and other drugs. The company?s technologies are used in 10 approved products; 3 partner programs that have been filed for with the FDA; and 12 development programs in human clinical trials. Its partnered products include NKTR-061, a Phase II clinical product for gram-negative pneumonias; and Ciprofloxacin Inhalation Powder, a Phase II clinical product for lung infections. The company?s partnered product portfolio also comprises Neulasta for neutropenia; PEGASYS for Hepatitis-C; Somavert for Acromegaly; PEG-INTRON for Hepatitis-C; Macugen for age-related macular degeneration; CIMZIA for Crohn's disease; MIRCERA for renal anemia and chronic kidney disease; CIMZIA for rheumatoid arthritis; Hematide, a Phase III product for Anemia; MAP0004, a Phase III product for Migraine; Macugen, a Phase II clinical trial product for diabetic macular edema and retinal vein occlusion; and CDP 791, a Phase II product for nonsmall cell lung cancer. In addition, Nektar?s proprietary products include NKTR-105 (PEGylated docetaxel) for colorectal and non-small-cell lung cancer; NKTR-102, a Phase II trial product for colorectal cancer, metastatic breast, metastatic cervical cancer, and platinum resistant ovarian cancer; NKTR-118, a Phase II product for opioid-induced constipation and other manifestations of opioid bowel dysfunction; and NKTR-063 (inhaled vancomycin), a proprietary antibiotic being developed for Gram-positive pneumonia, including MRSA infections, which is in Phase I clinical trials in the U.K. and scheduled to enter Phase II trials in the U.S. in the first half of 2009. The company was founded in 1990 and is headquartered in San Carlos, California.

NKTR (Nektar Therapeutics Inc)
Last Trade 17.27 Date 10/18/2019
Change % -2.82 % Price Change -0.50
Open 17.67 52 Week High 51.28
High 17.88 52 Week Low 15.635
Low 16.74 Type stock
Volume 4904111 Average Volume 3751064
Prev Close 17.77 Stock Exchange NASDAQ
Bid 17.22 Ask 17.42
Bid Size 1 Ask Size 2
1st Yr Estimated EPS Growth -0.0508 2nd Yr Estimated EPS Growth -0.2016
2 Years Forward Earning Yield -0.1123 2 Years Forward PE Ratio
2 Years EV/Forward EBIT -5.3987 2 Years EV/Forward EBITDA -5.7124
Book Value per Share 8.8841 Book Value Yield 0.5144
Buy Back Yield CAPE Ratio
Cash Return -0.1652 Cash Flow per Share -1.8182
Cash Flow Yield -0.1053 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.1482 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT -4.3225 EV / Forward EBITDA -4.5114
EV / Forward Revenue 9.1933 EV / Pre Tax Income
EV / Revenue 15.5971 EV / Total Asset 0.8849
Expected Dividend Growth Rate Free Cash Flow per Share -1.9743
Free Caash Flow Ratio Free Cash Flow Yield -0.1143
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.1407 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 1.943923 PB Ratio 10 Year Growth -0.136571
PB Ratio 3 Year Growth 152.577512 Cash Ratio 3 Year Average 1422.6863
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 44.328263 PE Ratio 10 Year Growth
PE Ratio 10 Year High 198.857143 PE Ratio 10 Year Low 7.088409
PE Ratio 1 Year Avg 9.077365 PE Ratio 1 Year High 11.22276
PE Ratio 1 Year Low 7.088409 PE Ratio 3 Year Avg 9.588745
PE Ratio 5 Year Avg 44.328263 PE Ratio 5 Year High 198.857143
PE Ratio 5 Year Low 7.088409 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 9.276428 Price Change 1 Month 0.94812
Price to Cash Ratio 1.997513 Price / EBITDA
Price to Sales Ratio 25.817146 Price to Sales Ratio 10 Year Growth 0.059261
Price to Sales Ratio 3 Year Avg 19.402509 Price to Sales Ratio 5 Year Avg 44.328263
Sale per Share 0.6689 Sales Yield 0.0387
Sustainable Growth Rate -0.2474 Tangible Book Value per Share 8.4476
Tangible Book Value per Share 3 year Avg 2.9936 Tangible Book Value per Share 5 year Avg 1.6962
Total Asset per Share 11.9792 Total Yield
Working Capital per Share 8.4636 Working Capital per Share 3 Year Avg 3.7389
Working Capital per Share 5 Year Avg 2.7303 Beta 3.056205